We are live on ! Find out more

Generate Biomedicines

GENB

Market cap $1.7B

13.21 USD

-1.25

8.64%

At close Updated Nov 2, 4:00 PM EST

Pre-market

After hours

13.47

+0.26

1.97%

1 day

-8.64%

5 days

6.96%

1 month

-3.51%

3 months

-7.88%

6 months

-8.64%

Year to date

4.43%

1 year

4.43%

5 years

4.43%

10 years

4.43%

About: Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 20%

Neutral 70%

Negative 10%

Generate Biomedicines to Participate in November Investor Conferences

SOMERVILLE, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc. (Nasdaq: GENB) (“Generate”) today announced that members of its management team will participate in presentations at the following investor conferences:

Generate Biomedicines to Participate in November Investor Conferences

Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases

Press release – No. 20 / 2026 Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases Collaboration will combine Zealand Pharma's expertise in metabolic health with Generate's proprietary generative AI platform to create multispecific drug candidates with tailored biological functions Generate will receive USD 30 million up-front, up to USD 35 million in early preclinical milestones, and a total of nearly USD 1.2 billion in milestones, plus tiered royalties for two initial programs, with an option to add a third The agreement will broaden Zealand Pharma's modality capabilities beyond peptides while extending The Generate Platform into obesity and other metabolic diseases Copenhagen, Denmark, October 13, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.

Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases

Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases

Collaboration will combine Zealand Pharma's expertise in metabolic health with Generate's proprietary generative AI platform to create multispecific drug candidates with tailored biological functions

Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases

Generate Biomedicines: The Dosing Interval Is The Moat, Not The Algorithm

Generate Biomedicines offers a compelling long-acting asthma biologic, golukibart (GB-0895), targeting twice-yearly dosing and broad phenotype efficacy. GENB leads the TSLP antagonist race with two global Phase 3 trials underway, aiming to displace Tezspire and capitalize on significant asthma and COPD market upside. Cash runway extends into early 2028, but Phase 3 trial costs and potential dilution before topline data are key risks to monitor.

Generate Biomedicines: The Dosing Interval Is The Moat, Not The Algorithm

Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored' CAR T Therapy for Ovarian Cancer

Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials First patient treated in new clinical trial underway at Roswell Park Treatment is designed to avoid pre-infusion chemotherapy and its side effects GB-5267 targets MUC16, a biomarker over-expressed in +80% of ovarian tumors BUFFALO, N.Y. and SOMERVILLE, Mass.

Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored' CAR T Therapy for Ovarian Cancer

Generate Biomedicines, Inc. (GENB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Generate Biomedicines, Inc. (GENB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Generate Biomedicines, Inc. (GENB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Generate Biomedicines Inc. to Participate in September Investor Conferences

SOMERVILLE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc. (Nasdaq: GENB) (“Generate”) today announced that members of its management team will participate in presentations at the following investor conferences:

Generate Biomedicines Inc. to Participate in September Investor Conferences

Proactive Investors

Generate Biomedicines stock jumps as post-IPO lock-up set to expire

Shares of Generate Biomedicines Inc (NASDAQ:GENB) jumped more than 20% on Tuesday as investors positioned ahead of the expiration of the company's post-IPO lock-up period. The lock-up, which ends Wednesday, will free company insiders, early investors and major shareholders to sell shares issued as part of Generate's $400 million initial public offering earlier this year, which included 25 million shares.

Generate Biomedicines stock jumps as post-IPO lock-up set to expire

Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update

SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advance with recruitment underway across all six global regions Phase 1b data for GB-0895 in COPD to be presented in a poster at the European Respiratory Society (ERS) Congress 2026 on Sept. 8 All patients enrolled in first cohort of the Phase 1 study for GB-4362 (MMAE neutralizer) Platform advancements extend across strategic collaborations Approximately $457.4 million in cash, cash equivalents, and marketable securities as of June 30, 2026 SOMERVILLE, Mass.

Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update

The Motley Fool

This Is Nvidia CEO Jensen Huang's Favorite Biotech Stock -- and You've Probably Never Heard of It

Generate Biomedicines had its IPO this past February. The company has had buy-in from Nvidia and Amgen.

This Is Nvidia CEO Jensen Huang's Favorite Biotech Stock -- and You've Probably Never Heard of It

See News Rankings

Price charts implemented using Lightweight Charts™